NeuroPhage Raises $9M For Neurodegenerative Diseases Treatment

NeuroPhage Pharmaceuticals, a privately held biotechnology company focused on the treatment and prevention of neurodegenerative diseases, announced that it has secured $9 million. The funding round that was completed by existing investors and private investors brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million. NeuroPhage, which focuses on treating diseases involving protein aggregation, was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University. View and share